
Strategic Intent: Rubedo’s Seno-Adaptive Bet On Longevity Medicine
Sep 21, 2026 - 40:09
Radio and PodcastLive Radio & Podcasts
One in ten women has endometriosis, yet treatment options remain largely unchanged for decades. Tanya Petrossian, CEO of EndoCyclic Therapeutics, explains how her company's non-hormonal peptide platform - now FDA-cleared...